Conclusions Fibrates have a significantly greater effect in reducing plasma Lp(a ) concentrations than statins .
Addition of fibrates to statins can enhance the Lp(a)-lowering effect of statins
Background Raised plasma lipoprotein(a ) ( Lp(a ) ) concentration is an independent and causal risk factor for atherosclerotic cardiovascular disease .
Several types of pharmacological approaches are under evaluation for their potential to reduce plasma Lp(a ) levels .
There is suggestive evidence that statins and fibrates , two frequently employed lipid-lowering drugs , can lower plasma Lp(a ) .
The present study aims to compare the efficacy of fibrates and statins in reducing plasma concentrations of Lp(a ) using a meta- analysis of r and omized head-to-head trials .
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
The effects of atorvastatin ( lipitor ) on cholesterol-rich and triglyceride-rich lipoproteins were evaluated in this multicenter trial . Following a 6-week baseline period , 47 patients with elevated cholesterol and triglyceride levels were treated with atorvastatin 10 mg once daily ( QD ) for the initial 12 weeks ( Period 1 ) increasing to 20 mg QD for the following 12 weeks ( Period 2 ) . At both the 10 and 20 mg doses , atorvastatin treatment result ed in significant reductions compared to pretreatment levels in low-density lipoprotein cholesterol ( LDL-C ) , total cholesterol ( TC ) , very low-density lipoprotein cholesterol ( VLDL-C ) , apolipoprotein ( apo ) B , apoB in LDL ( LDL-apo B ) , apo B in VLDL ( VLDL-apo B ) , lipoprotein (Lp)B , lipoprotein B-complex ( LpBc ) , triglycerides ( TG ) , low-density lipoprotein triglycerides ( LDL-TG ) , very low-density lipoprotein triglyceride ( VLDL-TG ) , high-density lipoprotein triglycerides ( HDL-TG ) , and apo C-III .  Atorvastatin 10 and 20 mg QD also result ed in significant increases in high-density lipoprotein cholesterol ( HDL-C ) , apo AI , and LpAII : B : C : D : E. Due to its unique ability to normalize both cholesterol-rich and triglyceride-rich particles , atorvastatin is a promising c and i date for monotherapy in a broad range of patients including those with varying degrees of hypercholesterolemia and hypertriglyceridemia
Conclusions Fibrates have a significantly greater effect in reducing plasma Lp(a ) concentrations than statins .
Addition of fibrates to statins can enhance the Lp(a)-lowering effect of statins
Background Raised plasma lipoprotein(a ) ( Lp(a ) ) concentration is an independent and causal risk factor for atherosclerotic cardiovascular disease .
Several types of pharmacological approaches are under evaluation for their potential to reduce plasma Lp(a ) levels .
There is suggestive evidence that statins and fibrates , two frequently employed lipid-lowering drugs , can lower plasma Lp(a ) .
The present study aims to compare the efficacy of fibrates and statins in reducing plasma concentrations of Lp(a ) using a meta- analysis of r and omized head-to-head trials .